Ex-Ru­bius CEO dusts him­self off at a dif­fer­ent Flag­ship biotech; Hutchmed switch­es things up dur­ing pipeline re­fo­cus

→ We led off Peer Re­view two weeks ago with what re­mains of Ru­bius Ther­a­peu­tics — and it’s not much. But ex-CEO Pablo Cagnoni has quick­ly re­bound­ed at an­oth­er Flag­ship biotech, tak­ing con­trol at a place where he’s been a board mem­ber for the last year. Cagnoni is suc­ceed­ing in­ter­im CEO John Mendlein at End­less RNA (eR­NA) biotech Laronde, which had the ex­cep­tion­al­ly lofty am­bi­tion of de­vel­op­ing 100 drugs by 2031 up­on its May 2021 launch and then raised $440 mil­lion in a Se­ries B to put the wheels in mo­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA